表紙
市場調查報告書

糖尿病治療藥的全球市場(2012年∼2024年)

Global Diabetes Care Drugs Market - Growth, Trends and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390670
出版日期 內容資訊 英文 95 Pages
商品交期: 2-3個工作天內
價格
糖尿病治療藥的全球市場(2012年∼2024年) Global Diabetes Care Drugs Market - Growth, Trends and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 95 Pages
簡介

2017年的全球糖尿病治療藥市場市場規模達到675億1,043萬美元,預計從2019年到2024年這段預測期間內,將以5.65%的年複合成長率成長。

本報告提供全球糖尿病治療藥市場調查,整體市場趨勢,各治療藥、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 競爭的激烈程度

第5章 市場區隔

  • 各治療藥物(以金額、數量為準,2012年∼2024年)
    • 口服抗糖尿病藥物
    • 胰島素
    • 非胰島素注射劑
    • 複合治療藥
  • 地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場指標

  • 第一型糖尿病人口(2012年∼2024年)
  • 第二型糖尿病人口(2012年∼2024年)

第7章 競爭情形

  • 企業簡介
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • 武田藥品工業
    • Pfizer
    • Janssen Pharmaceuticals
    • Astellas Pharma Inc.
    • Boehringer Ingelheim
    • Merck and Co.
    • AstraZeneca
    • Bristol Myers Squibb
    • Novartis
  • 企業佔有率分析
    • Novo Nordisk
    • Sanofi
    • Eli Lilly
    • AstraZeneca
    • Astellas Pharma Inc.
    • Janssen Pharmaceuticals
    • Merck and Co.
    • 其他

第8章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55895

Market Overview

  • The market size, in 2017, for the global diabetes drugs market was registered to be USD 67.5 billion, and the market is expected to record a CAGR of 5.65% during the forecast period, 2019-2024.
  • North America dominates the market, followed by Asia-Pacific.
  • Diabetes or diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate or one does not produce insulin (known as Type 1 diabetes), or because the body's cells do not respond properly to insulin (known as Type 2 diabetes), or both.
  • Approximately 10% of all diabetes cases are Type 1, and approximately 90% of all cases of diabetes worldwide are of Type 2.

Scope of the Report

The global diabetes care drugs market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) and by geography.

Key Market Trends

Rising Prevalence of Diabetes

  • As per a WHO report, the global prevalence of diabetes among adults of over 18 years had accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
  • Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
  • Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
  • Statistics prove that one in ten individuals in the world has diabetes and a rise in this trend is expected to take the situation to one in three by 2050 (according to the Center for Disease Control and Prevention).
  • The growing prevalence of diabetes is the major driver for the global diabetes care drugs market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.

The United States Leads the Diabetes Drugs Market in North America

  • In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
  • In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population in this region.

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market.

  • Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.
  • In 2015 and 2016, Lantus global sales were down by 11%, due to competition from other new drugs, biosimilars, and its own brand Toujeo.
  • September 2017: Insulin Tregopil, the first Oral Insulin, was under development by Biocon India, which is supported by JDRF.
  • March 2017: Zynquista (Sotagliflozin) was the first oral anti-diabetic drug approved in the United States for use by adults with Type 1 diabetes.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Oral Anti-diabetic drugs (Value and Volume 2012-2024)
      • 5.1.1.1 Biguanides
      • 5.1.1.1.1 Metformin
      • 5.1.1.2 Alpha-Glucosidase Inhibitors
      • 5.1.1.3 Dopamine -D2 Receptor Agonist
      • 5.1.1.3.1 Cycloset (Bromocriptin)
      • 5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
      • 5.1.1.4.1 Invokana (Canagliflozin)
      • 5.1.1.4.2 Jardiance (Empagliflozin)
      • 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
      • 5.1.1.4.4 Suglat (Ipragliflozin)
      • 5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • 5.1.1.5.1 Januvia (Sitagliptin)
      • 5.1.1.5.2 Onglyza (Saxagliptin)
      • 5.1.1.5.3 Tradjenta (Linagliptin)
      • 5.1.1.5.4 Vipidia/Nesina (Alogliptin)
      • 5.1.1.5.5 Galvus (Vildagliptin)
      • 5.1.1.6 Sulfonylureas
      • 5.1.1.7 Meglitinides
    • 5.1.2 Insulins (Value and Volume 2012-2024)
      • 5.1.2.1 Basal or Long-acting Insulin
      • 5.1.2.1.1 Lantus (Insulin Glargine)
      • 5.1.2.1.2 Levemir (Insulin Detemir)
      • 5.1.2.1.3 Toujeo (Insulin Glargine)
      • 5.1.2.1.4 Tresiba (Insulin Degludec)
      • 5.1.2.1.5 Basaglar (Insulin Glargine)
      • 5.1.2.2 Bolus or Fast-acting Insulin
      • 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
      • 5.1.2.2.2 Humalog (Insulin Lispro)
      • 5.1.2.2.3 Apidra (Insulin Glulisine)
      • 5.1.2.3 Traditional Human Insulin
      • 5.1.2.3.1 Novolin/Actrapid/Insulatard
      • 5.1.2.3.2 Humulin
      • 5.1.2.3.3 Insuman
      • 5.1.2.4 Biosimilar Insulin
      • 5.1.2.4.1 Insulin Glargine Biosimilars
      • 5.1.2.4.2 Human Insulin Biosimilars
    • 5.1.3 Non-insulin Injectable drugs (Value and Volume 2012-2024)
      • 5.1.3.1 GLP-1 Receptor Agonists
      • 5.1.3.1.1 Victoza (Liraglutide)
      • 5.1.3.1.2 Byetta (Exenatide)
      • 5.1.3.1.3 Bydureon (Exenatide)
      • 5.1.3.1.4 Trulicity (Dulaglutide)
      • 5.1.3.1.5 Lyxumia (Lixisenatide)
      • 5.1.3.2 Amylin Analogue
      • 5.1.3.2.1 Symlin (Pramlintide)
    • 5.1.4 Combination Drugs
      • 5.1.4.1 Combination Insulin
      • 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
      • 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
      • 5.1.4.2 Oral Combination
      • 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume 2012-2024)
      • 5.2.1.1.1 Oral Anti-diabetic Drugs
      • 5.2.1.1.2 Insulin
      • 5.2.1.1.3 Non-Insulin Injectable Drugs
      • 5.2.1.1.4 Combination Drugs
      • 5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.1.2 Canada (Value and Volume 2012-2024)
      • 5.2.1.2.1 Oral Anti-diabetic Drugs
      • 5.2.1.2.2 Insulin
      • 5.2.1.2.3 Non-Insulin Injectable Drugs
      • 5.2.1.2.4 Combination Drugs
      • 5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.1.3 Rest of North America (Value and Volume 2012-2024)
      • 5.2.1.3.1 Oral Anti-diabetic Drugs
      • 5.2.1.3.2 Insulin
      • 5.2.1.3.3 Non-Insulin Injectable Drugs
      • 5.2.1.3.4 Combination Drugs
      • 5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume 2012-2024)
      • 5.2.2.1.1 Oral Anti-diabetic Drugs
      • 5.2.2.1.2 Insulin
      • 5.2.2.1.3 Non-Insulin Injectable Drugs
      • 5.2.2.1.4 Combination Drugs
      • 5.2.2.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.2 Germany (Value and Volume 2012-2024)
      • 5.2.2.2.1 Oral Anti-diabetic Drugs
      • 5.2.2.2.2 Insulin
      • 5.2.2.2.3 Non-Insulin Injectable Drugs
      • 5.2.2.2.4 Combination Drugs
      • 5.2.2.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.3 Italy (Value and Volume 2012-2024)
      • 5.2.2.3.1 Oral Anti-diabetic Drugs
      • 5.2.2.3.2 Insulin
      • 5.2.2.3.3 Non-Insulin Injectable Drugs
      • 5.2.2.3.4 Combination Drugs
      • 5.2.2.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.4 Spain (Value and Volume 2012-2024)
      • 5.2.2.4.1 Oral Anti-diabetic Drugs
      • 5.2.2.4.2 Insulin
      • 5.2.2.4.3 Non-Insulin Injectable Drugs
      • 5.2.2.4.4 Combination Drugs
      • 5.2.2.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.5 United Kingdom (Value and Volume 2012-2024)
      • 5.2.2.5.1 Oral Anti-diabetic Drugs
      • 5.2.2.5.2 Insulin
      • 5.2.2.5.3 Non-Insulin Injectable Drugs
      • 5.2.2.5.4 Combination Drugs
      • 5.2.2.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.6 Russia (Value and Volume 2012-2024)
      • 5.2.2.6.1 Oral Anti-diabetic Drugs
      • 5.2.2.6.2 Insulin
      • 5.2.2.6.3 Non-Insulin Injectable Drugs
      • 5.2.2.6.4 Combination Drugs
      • 5.2.2.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
      • 5.2.2.7.1 Oral Anti-diabetic Drugs
      • 5.2.2.7.2 Insulin
      • 5.2.2.7.3 Non-Insulin Injectable Drugs
      • 5.2.2.7.4 Combination Drugs
      • 5.2.2.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume 2012-2024)
      • 5.2.3.1.1 Oral Anti-diabetic Drugs
      • 5.2.3.1.2 Insulin
      • 5.2.3.1.3 Non-Insulin Injectable Drugs
      • 5.2.3.1.4 Combination Drugs
      • 5.2.3.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.3.2 Brazil (Value and Volume 2012-2024)
      • 5.2.3.2.1 Oral Anti-diabetic Drugs
      • 5.2.3.2.2 Insulin
      • 5.2.3.2.3 Non-Insulin Injectable Drugs
      • 5.2.3.2.4 Combination Drugs
      • 5.2.3.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
      • 5.2.3.3.1 Oral Anti-diabetic Drugs
      • 5.2.3.3.2 Insulin
      • 5.2.3.3.3 Non-Insulin Injectable Drugs
      • 5.2.3.3.4 Combination Drugs
      • 5.2.3.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume 2012-2024)
      • 5.2.4.1.1 Oral Anti-diabetic Drugs
      • 5.2.4.1.2 Insulin
      • 5.2.4.1.3 Non-Insulin Injectable Drugs
      • 5.2.4.1.4 Combination Drugs
      • 5.2.4.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.2 South Korea (Value and Volume 2012-2024)
      • 5.2.4.2.1 Oral Anti-diabetic Drugs
      • 5.2.4.2.2 Insulin
      • 5.2.4.2.3 Non-Insulin Injectable Drugs
      • 5.2.4.2.4 Combination Drugs
      • 5.2.4.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.3 China (Value and Volume 2012-2024)
      • 5.2.4.3.1 Oral Anti-diabetic Drugs
      • 5.2.4.3.2 Insulin
      • 5.2.4.3.3 Non-Insulin Injectable Drugs
      • 5.2.4.3.4 Combination Drugs
      • 5.2.4.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.4 India (Value and Volume 2012-2024)
      • 5.2.4.4.1 Oral Anti-diabetic Drugs
      • 5.2.4.4.2 Insulin
      • 5.2.4.4.3 Non-Insulin Injectable Drugs
      • 5.2.4.4.4 Combination Drugs
      • 5.2.4.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.5 Australia (Value and Volume 2012-2024)
      • 5.2.4.5.1 Oral Anti-diabetic Drugs
      • 5.2.4.5.2 Insulin
      • 5.2.4.5.3 Non-Insulin Injectable Drugs
      • 5.2.4.5.4 Combination Drugs
      • 5.2.4.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.6 Vietnam (Value and Volume 2012-2024)
      • 5.2.4.6.1 Oral Anti-diabetic Drugs
      • 5.2.4.6.2 Insulin
      • 5.2.4.6.3 Non-Insulin Injectable Drugs
      • 5.2.4.6.4 Combination Drugs
      • 5.2.4.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.7 Malaysia (Value and Volume 2012-2024)
      • 5.2.4.7.1 Oral Anti-diabetic Drugs
      • 5.2.4.7.2 Insulin
      • 5.2.4.7.3 Non-Insulin Injectable Drugs
      • 5.2.4.7.4 Combination Drugs
      • 5.2.4.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.8 Indonesia (Value and Volume 2012-2024)
      • 5.2.4.8.1 Oral Anti-diabetic Drugs
      • 5.2.4.8.2 Insulin
      • 5.2.4.8.3 Non-Insulin Injectable Drugs
      • 5.2.4.8.4 Combination Drugs
      • 5.2.4.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.9 Philippines (Value and Volume 2012-2024)
      • 5.2.4.9.1 Oral Anti-diabetic Drugs
      • 5.2.4.9.2 Insulin
      • 5.2.4.9.3 Non-Insulin Injectable Drugs
      • 5.2.4.9.4 Combination Drugs
      • 5.2.4.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.10 Thailand (Value and Volume 2012-2024)
      • 5.2.4.10.1 Oral Anti-diabetic Drugs
      • 5.2.4.10.2 Insulin
      • 5.2.4.10.3 Non-Insulin Injectable Drugs
      • 5.2.4.10.4 Combination Drugs
      • 5.2.4.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
      • 5.2.4.11.1 Oral Anti-diabetic Drugs
      • 5.2.4.11.2 Insulin
      • 5.2.4.11.3 Non-Insulin Injectable Drugs
      • 5.2.4.11.4 Combination Drugs
      • 5.2.4.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
      • 5.2.5.1.1 Oral Anti-diabetic Drugs
      • 5.2.5.1.2 Insulin
      • 5.2.5.1.3 Non-Insulin Injectable Drugs
      • 5.2.5.1.4 Combination Drugs
      • 5.2.5.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.2 Iran (Value and Volume 2012-2024)
      • 5.2.5.2.1 Oral Anti-diabetic Drugs
      • 5.2.5.2.2 Insulin
      • 5.2.5.2.3 Non-Insulin Injectable Drugs
      • 5.2.5.2.4 Combination Drugs
      • 5.2.5.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.3 Egypt (Value and Volume 2012-2024)
      • 5.2.5.3.1 Oral Anti-diabetic Drugs
      • 5.2.5.3.2 Insulin
      • 5.2.5.3.3 Non-Insulin Injectable Drugs
      • 5.2.5.3.4 Combination Drugs
      • 5.2.5.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.4 Oman (Value and Volume 2012-2024)
      • 5.2.5.4.1 Oral Anti-diabetic Drugs
      • 5.2.5.4.2 Insulin
      • 5.2.5.4.3 Non-Insulin Injectable Drugs
      • 5.2.5.4.4 Combination Drugs
      • 5.2.5.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.5 South Africa (Value and Volume 2012-2024)
      • 5.2.5.5.1 Oral Anti-diabetic Drugs
      • 5.2.5.5.2 Insulin
      • 5.2.5.5.3 Non-Insulin Injectable Drugs
      • 5.2.5.5.4 Combination Drugs
      • 5.2.5.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
      • 5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
      • 5.2.5.6.1 Oral Anti-diabetic Drugs
      • 5.2.5.6.2 Insulin
      • 5.2.5.6.3 Non-Insulin Injectable Drugs
      • 5.2.5.6.4 Combination Drugs
      • 5.2.5.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2024)
  • 6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly
    • 7.1.4 Takeda
    • 7.1.5 Pfizer
    • 7.1.6 Janssen Pharmaceuticals
    • 7.1.7 Astellas
    • 7.1.8 Boehringer Ingelheim
    • 7.1.9 Merck and Co.
    • 7.1.10 AstraZeneca
    • 7.1.11 Bristol Myers Squibb
    • 7.1.12 Novartis
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly
    • 7.2.4 AstraZeneca
    • 7.2.5 Astellas
    • 7.2.6 Janssen Pharmaceuticals
    • 7.2.7 Merck and Co.
    • 7.2.8 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS